Camille Tlemsani

Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients

Olivier Huillard, Olivier Mir, Michaël Peyromaure et al. · British Journal of Cancer · 2013 · 224 citations · Full text

Medicine, Oncology, Pharmacology +15

SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures

Camille Tlemsani, Lőrinc Sándor Pongor, Fathi Elloumi et al. · Cell Reports · 2020 · 168 citations · Full text

Medicine, Molecular Biology, Oncology +17

<i>CDH1</i> germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study

Patrick R. Benusiglio, David Malka, Étienne Rouleau et al. · Journal of Medical Genetics · 2013 · 150 citations

Life Sciences, Genetics, Oncology +17

The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort

Diane Damotte, Sarah Warren, Jennifer Arrondeau et al. · Journal of Translational Medicine · 2019 · 150 citations · Full text

Medicine, Immunology, Oncology +17

Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study

Manuela Tiako Meyo, Anne Jouinot, Etienne Giroux‐Leprieur et al. · Cancers · 2020 · 112 citations · Full text

Medicine, Oncology, Pharmacology +17